Slightly fewer patients in the olmesartan group than in the placebo group had nonfatal cardiovascular events -- 81 of 2232 patients ( 3.6 % ) as compared with 91 of 2215 patients ( 4.1 % ) ( P = 0.37 ) -- but a greater number had fatal cardiovascular events -- 15 patients ( 0.7 % ) as compared with 3 patients ( 0.1 % ) ( P = 0.01 ) , a difference that was attributable in part to a higher rate of death from cardiovascular causes in the olmesartan group than in the placebo group among patients with preexisting coronary heart disease ( 11 of 564 patients [ 2.0 % ] vs. 1 of 540 [ 0.2 % ] , P = 0.02 ) .
